"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
Descriptor ID |
D000995
|
MeSH Number(s) |
D27.505.954.122.085.255
|
Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 2 | 6 | 8 |
1996 | 0 | 2 | 2 |
1997 | 1 | 2 | 3 |
1998 | 1 | 0 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 2 | 3 |
2003 | 0 | 1 | 1 |
2004 | 4 | 2 | 6 |
2005 | 2 | 1 | 3 |
2006 | 2 | 2 | 4 |
2007 | 1 | 0 | 1 |
2008 | 4 | 2 | 6 |
2009 | 4 | 5 | 9 |
2010 | 3 | 2 | 5 |
2011 | 7 | 5 | 12 |
2012 | 4 | 6 | 10 |
2013 | 5 | 4 | 9 |
2014 | 8 | 6 | 14 |
2015 | 6 | 4 | 10 |
2016 | 11 | 8 | 19 |
2017 | 15 | 3 | 18 |
2018 | 17 | 5 | 22 |
2019 | 13 | 4 | 17 |
2020 | 9 | 7 | 16 |
2021 | 2 | 7 | 9 |
2022 | 0 | 11 | 11 |
2023 | 0 | 9 | 9 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024 Mar 24; 10(1):22.
-
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nat Med. 2024 Mar; 30(3):896-904.
-
Anti-Tuberculosis Potential of OJT008 against Active and Multi-Drug-Resistant Mycobacterium Tuberculosis: In Silico and In Vitro Inhibition of Methionine Aminopeptidase. Int J Mol Sci. 2023 Dec 05; 24(24).
-
[Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)]. Pneumologie. 2024 Jan; 78(1):35-46.
-
Emerging bedaquiline-resistant tuberculosis. Lancet Microbe. 2023 12; 4(12):e964-e965.
-
Impact of Mycobacterium tuberculosis strain type on multidrug-resistant tuberculosis severity, Republic of Moldova. J Infect. 2023 Dec; 87(6):588-591.
-
Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2023 07 15; 208(2):130-131.
-
[Treatment of tuberculosis: what is new?] Inn Med (Heidelb). 2023 Jul; 64(7):701-707.
-
Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova. Emerg Infect Dis. 2023 05; 29(5):1046-1050.
-
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023 04; 23(4):e122-e137.